DNDi Director: ‘Reality Check’ Needed For Neglected Diseases 11/02/2014 by Intellectual Property Watch 2 Comments Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)Research and development into neglected diseases – those predominately affecting poorer populations and for which there is little commercial incentive – is undergoing “remarkable advances and rude set-backs,” says Bernard Pécoul, executive director of the Drugs for Neglected Diseases initiative (DNDi). Now, governments need to show stronger leadership in bringing about long-term solutions, he said. Pécoul expressed his views in a piece published by DNDi this month, entitled, “Time for a Reality Check for Neglected Diseases.” The World Health Organization has been working for years to address the neglected disease market failure but so far has only been able to come up with a few “R&D demonstration projects,” of which DNDi is a beneficiary, and a plan for a Global Health R&D Observatory, which will collect data (IPW, WHO, 25 January 2014). But, Pécoul said, “These steps, taken alone, certainly do not respond to the magnitude of the problem of ensuring innovation and access to health technologies for millions of people living outside the lucrative market.” He noted that many have sought a global instrument to address the problem, but he advocated working constructively with what has been agreed. The proposal for an R&D instrument was pulled from the table due to developed country opposition (IPW, WHO, 29 November 2012). DNDi has been working since its inception to bring innovative ways to deliver new therapies to populations in need, he said. But, he added, “I cannot emphasize enough that these are ad hoc fixes to the systemic problems in this field. Public leadership is needed to set up the favourable environment required to support all the actors involved in control, prevention, and elimination of certain diseases.” He mentioned the recent announcement by pharmaceutical company AstraZeneca to discontinue work on neglected diseases, and South Africa’s effort to reform its IP policy, which recently came under pressure from foreign companies (IPW, Developing Country Policy, 22 January 2014). Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window) Related "DNDi Director: ‘Reality Check’ Needed For Neglected Diseases" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Riaz Tayob says 19/02/2014 at 10:47 am Well Mary Moran’s work argued that PDPs were the solution during the neglected diseases work on innovation strategies. At the time I said that there was a leap of logic in the paper, between diagnosis and prescription. The diagnosis offered by Moran could have found prescriptions in a range of other options (patent pools, Health Impact Fund, Medical R&D treaty). Locating Moran’s work in the political economy of health diplomacy, aside from the leap, it was a solution that was used (by others, but also somewhat by the author or those who followed her) undermined other solutions – because it was touted as THE solution. So perhaps now a more realist vantage will be taken (or perhaps not) that BigPharma is not interested in health, but in profit. Sure PDPs have a role to play, but the BigPharma strategy has been to admit no exception to the market based IPR model. Not even PDPs. We now have high expectations of Moran to work to ensure these models work, instead of relegating important institutions like DNDi to beggars shining their begging bowls… as Bernard now has to do… Reply